Electromedical & Electrotherapeutic Apparatus · SIC 3845

POSITRON CORP

POSC

Watch

Latest revenue

as of

Latest net income

as of

Net margin

as of

Price · 5Y

+24.5% / yr 10.8 pts / yr vs S&P 500 198.4% total
Compare:

Live market

delayed ≤15 min
$1.85
3.35%
Market cap
$60.8M
Enterprise value
$60.8M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$2.74
52-wk low
$1.25
Beta
Shares out
32.8M

5-year trend

No quarterly data ingested yet for this company.

What this company does

AI

Item 1. Business Organization Positron Corporation (the “Company” or “Positron”) was incorporated under the laws of the State of Texas in 1983. Unless the context requires otherwise, in this report the terms “we,” “us”, “our”, “the Company”, and “Positron” refer to Positron Corporation. Corporate History Positron Corporation was incorporated as a Texas corporation in 1983 with its corporate headquarters in North Tonawanda, New York. Nature of Business. Positron is a medical technology company that co-develops, manufactures and sells PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the…

AI summary unavailable — showing raw filing excerpt

Generated from POSC's filing dated 2026-03-31

Key risks

AI

Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. You should consider carefully the risks, uncertainties and other factors described below, in addition to the other information set forth in this Form 10-K, before making an investment decision. Any of these risks, uncertainties and other factors could materially and adversely affect our business, financial condition, results of operations, cash flows or prospects. In that case, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. See also “Cautionary Statement Regarding Forward-Looking Statements.” Risk Associated with Business Activities…

AI summary unavailable — showing raw filing excerpt

Generated from POSC's filing dated 2026-03-31

Profitability

Gross margin

-458.2%

687.1%

Operating margin

-2275.1%

506.2%

Net margin

-2297.8%

467.4%

Return on equity

-734.4%

302.7%

Return on assets

-265.1%

100.6%

Leverage

Debt / equity

1.77×

147.3%

Long-term debt / equity

0.11×

387.6%

Debt / assets

63.9%

53.2%

Earnings tracker

Not enough quarterly history for POSC yet to draw an earnings tracker.

Industry trend

Electromedical & Electrotherapeutic Apparatus · SIC 3845

Your notes

Keep private notes on POSC — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

No insider transactions on file for POSC in the last 12 months.

Source: SEC Form 4 filings. Backfill runs nightly.

Who owns POSC

No institutional holdings on file for POSC yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once POSC's latest filing finishes processing.